US Stock Insider Trading | Lilly discloses one insider transaction on February 12

K-LinePoet · 2026-03-09T18:42:18+00:00

Eli Lilly disclosed insider trading activity on February 12, 2026, with several executives purchasing large amounts of company stock on February 9. Rau Diogo bought 4,599 shares, totaling $4,804,600. The overall transactions indicate the executives' confidence in the company's future. Eli Lilly was founded in 1901 and focuses on the research, development, and manufacturing of human medicines, with operations spanning 90 countries worldwide.

K-LinePoet

2026-03-09 18:42:18

Abstract generation in progress

On February 12, 2026, Eli Lilly (LLY) disclosed one insider transaction. Executive Rau Diogo purchased 4,599 shares on February 9, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share (USD)	Total Amount (USD)
February 12, 2026	Executive	Rau Diogo	February 9, 2026	Buy	4,599	1,044.67	4.8046 million
February 11, 2026	Executive	Jonsson Patrik	February 9, 2026	Buy	4,818	1,044.67	5.0333 million
February 11, 2026	Director	Ricks David A	February 9, 2026	Buy	38,900	1,044.67	40.6519 million
February 11, 2026	Executive	Skovronsky Daniel	February 9, 2026	Buy	15,500	1,044.67	16.2424 million
February 11, 2026	Executive	Custer Kenneth L.	February 9, 2026	Buy	659	1,044.67	688,700
February 11, 2026	Executive	Brown Adrienne S	February 9, 2026	Buy	1,196	1,044.67	1,249,700
February 11, 2026	Executive	Dozier Eric	February 9, 2026	Buy	3,512	1,044.67	3.6692 million
February 11, 2026	Executive	Montarce Lucas	February 9, 2026	Buy	1,365	1,044.67	1.4265 million
February 11, 2026	Executive	Hakim Anat	February 9, 2026	Buy	8,277	1,044.67	8.6477 million
February 11, 2026	Executive	Yuffa Ilya	February 9, 2026	Buy	4,162	1,044.67	4.3484 million

[Company Profile]

Eli Lilly was founded in Indiana in 1901, building on a pharmaceutical manufacturing business established in 1876 by Colonel Lilly in Indianapolis. The company focuses on discovering, developing, manufacturing, and marketing human medicines. Its goal is to combine care and discovery to create drugs that improve lives worldwide. Long-term success depends on continuously discovering or acquiring, developing, and commercializing innovative medicines. The company produces and distributes products through factories located in the United States, including Puerto Rico, as well as in Europe and Asia, with sales covering approximately 90 countries.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.